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Abstract: The Food and Drug Administration Amendments Act of 2007 mandated that   sponsors 
of applicable studies must provide results within one year of study completion. We aimed to 
analyze the factors associated with reporting of results from interventional studies registered 
on ClinicalTrials.gov. On May 20, 2010, we retrieved 20 available fields from 57,233 closed 
studies on the website and identified 31,161 interventional studies that were required to post 
results. We compared the proportion of studies with results versus studies without results by 
age, gender, and disease status of participants, by interventions, sponsors, phase of clinical 
trials, and completion dates. The results of studies were reported for 4.7% of applicable studies, 
8% of industry-sponsored studies, 7.5% of Phase II and 6.5% of Phase IV clinical trials, 4.9% 
of drug studies, and 0% of genetic studies. Withdrawn (n = 486) and suspended (n = 414) 
interventions did not provide results. The percentage of studies with results varied from 0% 
to 21% among different sponsors. The first studies with results were completed in 1992. The 
proportion of studies with results increased over time. Completion dates were not available for 
7446 studies. The database does not have fields available to facilitate routine analysis of the rate 
of compliance with federal law for posting results. The analysis of accuracy of the protocols 
in relation to the results and publications is not possible without time-consuming evaluation of 
individual postings and individual publications.
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Introduction
Transparency in designing, conducting, and reporting of human experiments and 
observational studies is essential to guarantee the integrity of clinical research.1 
Registration of clinical trials with information about study sponsors and protocols 
makes clinical research more transparent. In 2000, the National Institutes of Health 
(NIH) requested that clinical trials assessing pharmacologic treatments for serious or 
life-threatening diseases be registered in the ClinicalTrials.gov online database. This 
website was developed by the National Library of Medicine as an information service 
for the NIH and the US Department of Health and Human Services.2 However, at that 
time, NIH policy did not require mandatory registration of all human studies. In 2005, 
the World Association of Medical Editors started to require mandatory registration 
of all clinical studies as a condition of publication.3 Sponsors must now provide the 
World Health Organization (WHO) with a minimum dataset of information, including 
details of study design, recruitment activities, ethics review of research, target sample 
size, conditions of eligibility for subjects to participate in the study, and primary 
and secondary outcomes.4 Stakeholders can find detailed information about study Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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protocols on ClinicalTrials.gov, but study results are not yet 
c  onsistently available online.
Selective publication of positive results and outcomes5–7 
led to further scrutiny and called for public disclosure of study 
results. The Food and Drug Administration Amendments Act 
(FDAAA) of 2007 mandated that sponsors of applicable stud-
ies must provide study flow, baseline subject characteristics, 
and outcomes after active and control interventions within one 
year of study completion.8 The FDAAA regulations defined 
the following clinical trials as needing to adhere to the require-
ments: Phase II–IV interventional studies, studies involving 
any drugs, biological products, or medical devices regulated 
by the FDA, studies having at least one site in the US or which 
are conducted under an investigational new drug application 
or investigational device exemption; and studies initiated or 
ongoing as of September 27, 2007, or later.9–12 Results can be 
posted within three years of completion of the study for trials 
investigating off-label use of previously approved drugs.
Registration of clinical trials on ClinicalTrials.gov 
improved the transparency of clinical research tremen-
dously.13–15 Stakeholders can find the WHO minimum dataset 
for the design of 92,385 studies.16 Harvard University has 
recognized the achievement of this website with their Inno-
vations in American Government Award.17 The degree of 
sponsor compliance with federal law in providing results of 
studies on ClinicalTrials.gov has not been examined as yet. 
We aimed to examine the completeness of the posted study 
designs and factors associated with reporting study results.
Methods
We retrieved all closed studies from ClinicalTrials.gov as of 
May 20, 2010. We retrieved all 20 available fields, including 
Table 1 Distribution of the studies closed in www.clinicaltrials.
gov on 20 May 2010
Category Frequency Percentage
Age
Adult 10,254 17.92
Adult/senior 32,678 57.1
Child 3428 5.99
Child/adult 2544 4.44
Child/adult/senior 8158 14.25
Senior 171 0.3
Gender Frequency missing  
(n = 393)
Both 48,224 84.84
Female 5408 9.51
Male 3208 5.64
Funding sources
industry 22,288 38.94
industry with other  
funding sources
4835 8.45
Recruitment
Active, not recruiting 13,751 24.03
Approved for marketing 16 0.03
Completed 36,992 64.63
enrolling by invitation 1330 2.32
no longer available 24 0.04
Suspended 587 1.03
Temporarily not available 7 0.01
Terminated 3554 6.21
Withdrawn 685 1.2
Withheld 287 0.5
Study types Frequency missing  
(n = 287)
expanded access 47 0.08
interventional 48,859 85.8
Observational 8040 14.12
Recruitment
Active, not recruiting 13,751 24.03
Approved for marketing 16 0.03
Completed 36,992 64.63
enrolling by invitation 1330 2.32
no longer available 24 0.04
Suspended 587 1.03
Temporarily not available 7 0.01
Terminated 3554 6.21
Withdrawn 685 1.2
Withheld 287 0.5
Study results
has results 1793 3.13
no results available 55,440 96.87
Phases Frequency missing  
(n = 16,589)
Phase 0 176 0.43
Phase i 7163 17.62
Phase ii 12,775 31.43
Phase iii 10,657 26.22
Phase ii–iii 1182 2.91
Phase iV 6488 15.96
Phase i–ii 2203 5.42
(Continued)
Table 1 (Continued)
Category Frequency Percentage
Interventions Frequency missing  
(n = 5908)
Behavioral 3297 6.42
Biological 3947 7.69
Device 3303 6.44
Diet 112 0.22
Dietary supplement 912 1.78
Disease management 8 0.02
Drug 33,605 65.47
education 66 0.13
genetic 250 0.49
Other 1815 3.54
Procedure 3688 7.19
radiation 207 0.4
exercise 115 0.22Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Table 2 Age and gender distribution of the interventional, active, not recruiting studies applicable to reporting the results (Phase 0–i 
excluded)
Age Gender Has results No results available n Percentage with results
Adult Both 151 3807 3958 3.82
Female 39 876 915 4.26
Male 6 410 416 1.44
Total 196 5093 5289 3.71
Frequency missing (n = 10)
Adult/senior Both 787 15,719 16,506 4.77
Female 46 1348 1394 3.30
Male 28 708 736 3.80
Total 861 17,775 18,636 4.62
Frequency missing (n = 16)
Child Both 157 1951 2108 7.45
Female 6 34 40 15.00
Male 0 31 31 0.00
Total 163 2016 2179 7.48
Child/adult Both 30 1066 1096 2.74
Female 10 151 161 6.21
Male 1 23 24 4.17
Total 41 1240 1281 3.20
Frequency missing (n = 1)
Child/adult/senior Both 113 2987 3100 3.65
Female 12 385 397 3.02
Male 4 119 123 3.25
Total 129 3491 3620 3.56
Frequency missing (n = 35)
Senior Both 4 82 86 4.65
Female 0 8 8 0.00
Male 0 0 0
Total 4 90 94 4.26
Table 3 Funding distribution, phases, and completion status of the interventional, active, not recruiting studies applicable to reporting 
of results (Phase 0–i excluded)
Funding source Has results No results available n Percentage with results
Total 1394 29,767 31,161 4.47
industry 1126 12,789 13,915 8.09
industry with other sources 72 2644 2716 2.65
national institutes of health 23 2214 2237 1.03
Other/national institutes of health 19 1367 1386 1.37
Other/unknown 15 840 855 1.75
network/national institutes of health 2 665 667 0.30
US Federal 5 444 449 1.11
national institutes of health/other 0 366 366 0.00
Phases
Total 1268 23,268 24,536 5.17
Phase i–ii 26 1444 1470 1.77
Phase ii 283 8788 9071 3.12
Phase ii–iii 19 798 817 2.33
Phase iii 613 7555 8168 7.50
Phase iV 327 4683 5010 6.53
Frequency missing (n = 6625)
Completion status
Completed 1243 25,390 26,633 4.67
enrolling by invitation 0 768 768 0.00
Suspended 0 414 414 0.00
Terminated 151 2709 2860 5.28
Total 1394 29,767 31,161 4.47
Withdrawn 0 486 486 0.00Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Figure 1 Time trend in percentage of interventional studies with results among all applicable closed studies.
Table 4 Distribution of conditions of subjects in closed interventional, active, not recruiting studies applicable to reporting of results 
(Phase 0–i excluded)
Conditions Has results No results available n Percentage with results
Total 1394 29,763 31,157 4.47
Largest number with results
Diabetes 99 1378 1477 6.70
hypertension 35 435 470 7.45
Human immunodeficiency virus 33 1165 1198 2.75
Asthma 30 513 543 5.52
Largest number closed studies
Breast cancer 16 490 506 3.16
Schizophrenia 18 431 449 4.01
Pain 13 342 355 3.66
Obesity 4 351 355 1.13
Leukemia 4 319 323 1.24
Lymphoma 2 320 322 0.62
Prostate cancer 12 301 313 3.83
Osteoarthritis 13 245 258 5.04
Influenza 25 232 257 9.73
Cardiovascular disease 3 233 236 1.27
Colorectal cancer 2 233 235 0.85
rheumatoid arthritis 12 219 231 5.19
Major depression 13 206 219 5.94
Lung cancer 3 216 219 1.37
Depression 3 210 213 1.41
Anemia 12 192 204 5.88
Frequency missing (n = 4)  
the ClinicalTrials.gov identifier, age group, gender, disease 
status of the eligible subjects, and examined interventions, 
recruitment status, study sponsors, study type and design, 
phase of clinical trials, start and completion dates, and 
posting of study results. Field locations were as described 
online at http://prsinfo.clinicaltrials.gov/definitions.html. 
We used the exact data provided by the sponsors. We further 
categorized interventions as behavioral, biological, device, 
dietary supplements, disease management, drug,   education, 
genetic, procedural, and exercise. We also redefined Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Table 5 Sponsors of the closed interventional, active, not recruiting studies applicable to reporting of results (Phase 0–i excluded)
Sponsors Has results No results available n Percentage with results
Total 1394 29,767 31,161 4.47
Largest number with the results
glaxoSmithKline 115 728 843 13.64
Pfizer 99 604 703 14.08
Merck 93 412 505 18.42
eli Lilly and Company 76 283 359 21.17
Schering-Plough 43 220 263 16.35
Boehringer ingelheim Pharmaceuticals 37 181 218 16.97
Sanofi-aventis 36 590 626 5.75
Alcon research 35 131 166 21.08
UCB inc. 33 135 168 19.64
Abbott 25 163 188 13.30
Bayer 23 206 229 10.04
Wyeth 23 241 264 8.71
Takeda global research and Development Center inc. 21 85 106 19.81
Results number of closed applicable studies
novartis Pharmaceuticals 5 694 699 0.72
AstraZeneca 17 422 439 3.87
national institute of Allergy and infectious Diseases 8 386 394 2.03
national heart, Lung, and Blood institute 6 337 343 1.75
Department of Veterans Affairs 1 324 325 0.31
national institute of Mental health 4 239 243 1.65
national Cancer institute 0 208 208 0.00
Memorial Sloan-Kettering Cancer Center/national  
Cancer institute
0 190 190 0.00
hoffmann-La roche 4 183 187 2.14
Bristol-Myers-Squibb 17 168 185 9.19
Johnson and Johnson Pharmaceutical research  
and Development, LLC
7 163 170 4.12
novo nordisk 12 155 167 7.19
national institute of Diabetes and Digestive  
and Kidney Diseases
2 159 161 1.24
Amgen 3 150 153 1.96
national Center for Complementary  
and Alternative Medicine
2 132 134 1.49
Astellas Pharma inc 1 121 122 0.82
north Central Cancer Treatment group/national  
Cancer institute
0 114 114 0.00
national institute on Drug Abuse 1 109 110 0.91
  conditions into larger diagnostic categories with the first 
disease stated. For example, when the condition was defined 
as “arthralgia, pain assessment”, we analyzed it under the 
category of “  arthralgia”. The available data do not have a 
single field to define the studies that are applicable to the US 
Public Law 110-85 (FDAAA), Title VIII, Section 801 for 
mandatory reporting of results. Therefore, we defined closed 
not-recruiting interventional trials, excluding Phase 0–I 
trials, as applicable to comply with FDAAA regulations.
We calculated descriptive frequency statistics without for-
mal hypothesis testing because we did not sample the data but 
rather analyzed all closed studies available. We then compared 
the proportions of studies having results with the proportions 
of studies without results in categories of age, gender, disease 
status, interventions, study sponsorship, types, and completion 
dates. All calculations were performed with frequency proce-
dure using SAS 9.1 software (SAS Institute Inc., Cary, NC).
Results
We retrieved 57,299 records but eliminated 66 records with 
misplaced fields, leaving a total of 57,233 records for analysis. 
We analyzed the completeness of the minimum dataset and 
found that 393 studies did not provide the gender for eligible 
subjects, 287 studies did not specify the type of study, and 5908 
did not specify intervention or exposure (Table 1). We noticed 
a marked inconsistency in the   classification and reporting of Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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patient conditions, which made statistical analysis difficult. 
For example, “non small cell lung cancer” was reported vari-
ously as “non-small cell lung cancer”, “non small cell lung 
carcinoma”, or “NSCLC”. More than 50% of the studies 
included adult subjects, and 85% of all studies recruited both 
genders. Children and seniors were included in a very small 
proportion of studies. More than 60% of closed studies were 
completed, and more than 65% of closed studies examined 
the effects of pharmacologic treatments. A total of 39% of 
all studies were sponsored by industry. Most of the studies 
(97%) did not have their results posted on the website.
Of 31,161 applicable closed interventional studies, 4.5% 
had results available. Proportions of studies with results 
  contained similar age and gender groups (Table 2).   Studies with 
children as subjects tended to report results more   frequently. 
Industry-sponsored studies reported results more often (8.1%) 
than nonindustry-funded studies (Table 3). Phase III and IV 
clinical trials reported results more often (total 14%) compared 
with Phase II trials (3%, Table 3). Suspended interventions 
(n = 414) and withdrawn interventions (n = 486) did not provide 
results or reasons for the cause of suspension or withdrawal 
(Table 3). The first studies containing results (n = 3) were 
sponsored by Merck and added to the database in 2009. These 
three studies are listed as NCT00882440, NCT00886600, 
and NCT00887250, and were completed in 1992. Among the 
applicable closed interventional studies, 7446 did not provide 
a completion date. The proportion of the studies with results 
increased over time (see Figure 1).
Among the applicable 31,161 closed interventional studies, 
the studies of hypertension and influenza reported results more 
Table 6 Treatments that were examined in the closed interventional, active, not recruiting studies applicable to reporting of results 
(Phase 0–i excluded)
Interventions Has results No results available n Percentage with results
Total (n = 4 missing) 1394 29,763 31,157 4.47
Biological 165 1740 1905 8.66
Device 84 1914 1998 4.20
Drug 1045 20,342 21387 4.89
genetic 0 48 48 0.00
Interventions tested in largest number of studies
Topiramate 0 66 66 0.00
epoetin-alfa 0 71 71 0.00
risperidone 0 64 64 0.00
Buprenorphine 0 39 39 0.00
Zidovudine 0 33 33 0.00
Levetiracetam 1 30 31 3.23
Aripiprazole 1 28 29 3.45
Bortezomib 0 28 28 0.00
etanercept 1 27 28 3.57
Vildagliptin 0 28 28 0.00
Thalidomide 0 25 25 0.00
Atorvastatin 1 23 24 4.17
esomeprazole 1 23 24 4.17
Levitra/placebo 1 23 24 4.17
Pregabalin 3 20 23 13.04
Procedure: acupuncture 0 23 23 0.00
rituximab 1 22 23 4.35
nitrous oxide 0 21 21 0.00
Arsenic trioxide 0 20 20 0.00
Interventions with largest number of reported results
rotigotine 9 7 16 56.25
Dexlansoprazole Mr/dexlansoprazole Mr/placebo 6 0 6 100.00
Pemetrexed 5 8 13 38.46
Pemetrexed/cisplatin 5 4 9 55.56
Biological: engerix™-B 4 0 4 100.00
Telavancin/vancomycin 4 0 4 100.00
Atomoxetine 3 15 18 16.67
Duloxetine/placebo 3 7 10 30.00
Abbreviation: MR, modified release.Clinical Pharmacology:   Advances and Applications 2010:2 submit your manuscript | www.dovepress.com
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Table 8 Patient conditions in withdrawn and suspended interventions applicable to reporting of results by type of treatment (shown 
if $10 interventions). The results are not available for all studies
Withdrawn interventions Biological Device Drug Procedure Radiation Total
Total 20 47 341 45 2 486
Breast cancer 3 0 12 0 0 16
Diabetes 1 0 9 2 0 12
Asthma 1 1 7 2 0 11
Human immunodeficiency virus 4 0 5 0 0 11
Suspended interventions
Total 50 43 254 41 1 414
Prostate cancer 1 0 8 1 0 11
Brain and central nervous system tumors 2 0 8 0 0 10
Human immunodeficiency virus 1 0 8 1 0 10
Leukemia 3 0 6 1 0 10
Melanoma 6 0 4 0 0 10
Table 7 Terminated interventional, active, not recruiting studies 
applicable to reporting of results (Phase 0–i excluded) by type of 
condition (shown for $20 total studies)
Conditions With 
results
No results n Percentage 
with results
Total 151 2709 2860 5.28
Diabetes 13 135 148 8.78
human 
immunodeficiency virus
5 94 99 5.05
Breast cancer 2 52 54 3.70
Lymphoma 0 53 53 0.00
Schizophrenia 2 41 43 4.65
Prostate cancer 5 35 40 12.50
Anemia 5 30 35 14.29
Pain 0 33 33 0.00
Leukemia 3 29 32 9.38
non small cell lung cancer 7 47 54 12.96
Obesity 0 31 31 0.00
Asthma 4 24 28 14.29
heart failure 0 27 27 0.00
Colorectal cancer 0 26 26 0.00
Osteoarthritis 1 22 23 4.35
Myeloma 0 22 22 0.00
Ovarian cancer 1 20 21 4.76
rheumatoid arthritis 4 17 21 19.05
Crohn’s disease 1 19 20 5.00
hypertension 1 19 20 5.00
often (7.5% and 9.7%, respectively, Table 4). The most com-
monly reported examined disease states included breast cancer, 
schizophrenia, and pain. Most of the closed studies of these 
conditions did not report the results (Table 4). The proportion 
of studies with results varied substantially between different 
sponsors (Table 5). Several pharmaceutical firms, including 
GlaxoSmithKline, Pfizer, Merck, and Eli Lilly and Company, 
sponsored more than 50 studies each and provided the results 
for more than 10% of the total sponsored studies. Two pharma-
ceutical firms, ie, Alcon Research and Eli Lilly and Company, 
provided results for more than 20% of applicable sponsored 
studies. Several sponsors did not provide results for funded 
studies. For instance, the National Cancer Institute sponsored 
208 closed interventions without results and Memorial Sloan-
Kettering Cancer Center sponsored 190 closed interventions 
without results. Genetic treatments were examined in 48 closed 
studies. None of the genetic studies provided results (Table 6). 
The studies of several drug, including zidovudine, risperidone, 
and vildagliptin, did not report their results.
Of 31,161 applicable closed interventional studies, 2860 
were terminated and 5.3% of 2860 reported results (Table 7). 
In terminated studies, the most common diseases involved 
were diabetes and human immunodeficiency virus. Of the 
terminated studies in prostate cancer, anemia, asthma, and 
rheumatoid arthritis, more than 10% reported results. The 
terminated studies of subjects with lymphoma, pain, obesity, 
heart failure, and colorectal cancer did not provide results. The 
majority of interventions that were suspended or withdrawn 
examined the effects of drugs (Table 8). Breast cancer and 
prostate cancer were among the most common conditions for 
trials which were suspended or had interventions withdrawn.
Discussion
We found that a statistical analysis of compliance with 
  mandatory reporting of results was difficult to perform. 
  Missing or inconsistently reported study details, including 
patient diseases, study completion dates, and reported inter-
ventions may lead to wrong conclusions about a sponsor’s 
compliance with federal law regarding study registration 
and reporting of outcomes. We could not identify a single 
well-defined field that has applicability status of individual 
studies to provide results. One variable provides information 
about the posting of the results. The changes in protocols 
and deviations from the planned presentation of the primary Clinical Pharmacology: Advances and Applications
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outcomes and safety outcomes were not easy to analyze with-
out time-consuming evaluation of each study. Reporting of 
studies completed before September 2007 was available in 
a small proportion of the interventions, when the sponsors 
decided to comply.
Both clinicians and the general public need complete 
and accurate information about study protocols and results.9 
Stakeholders should be able to find a clear description of 
interventions, including prior FDA approvals, off-label evalu-
ations, investigational new drug applications and numbers, and 
investigational device exemptions, as well as the applicability 
of reported results.18–20 Critical appraisal of the protocols and 
reported results on a regular basis by clinical epidemiologists 
may be worthwhile to ensure integrity of the clinical research 
reported on ClinicalTrials.gov.   Clinicians and patients need 
independent access to protocols and   market approval status of 
the tested interventions. Finally, our analysis found that none of 
the suspended or withdrawn studies reported either the baseline 
characteristics of enrolled subjects or the exact reasons for 
terminating the study. Posting the results of a study should be 
mandatory for all trials, regardless of prior FDA approval.9,11
Our study had several limitations. We defined the 
applicability of studies without evaluation of the market status 
of individual studies. We did not analyze deviations from the 
protocols when reporting the results. We did not analyze whether 
the sponsors posted the study results in a timely manner accord-
ing to the expected date. Future research should analyze time 
intervals between completion of the study, posting of results, 
and publication of the results in peer-reviewed journals.
We conclude that compliance with the requirements to 
post results of closed studies is low for both industry- and 
nonindustry-sponsored studies. The need for studies to report 
the results should be identified in the database during the 
registration of the studies.
Acknowledgment
The authors would like to thank Marilyn Eells and Michele 
Rockne for editing and formatting the manuscript.
Disclosure
The author reports no conflict of interest in this work.